Stock traders buy high volume of Liquidia put options (NASDAQ: LQDA)

Liquidia Co. (NASDAQ:LQDA – Get Rating) was the recipient of unusually heavy options trading activity on Thursday. Stock traders bought 6,623 put options on the stock. This is an increase of approximately 135% from the average volume of 2,824 puts.

Wall Street analysts predict growth

Several research firms have recently commented on LQDA. Wedbush downgraded Liquidia shares from a “neutral” rating to an “underperforming” rating and lowered their target price for the stock from $4.00 to $3.00 in a report released Thursday. Needham & Company LLC began covering Liquidia shares in a report on Thursday. They issued a “buy” rating and a target price of $12.00 on the stock. Bank of America assumed coverage for Liquidia shares in a Thursday, May 26, report. They issued a “buy” rating and a target price of $12.00 on the stock. LADENBURG THALM/SH SH assumed coverage for Liquidia shares in a Friday, July 22 research report. They issued a “buy” rating and a price target of $15.00 on the stock. Finally, BTIG Research raised its price target on Liquidia shares from $14.00 to $17.00 and gave the stock a “buy” rating in a Wednesday, July 20 research report. One financial analyst gave the stock a sell rating and five gave the company’s stock a buy rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.50.

Liquidia institutional trading

Several hedge funds have recently changed their holdings to LQDA. Soleus Capital Management LP acquired a new position in shares of Liquidia during the fourth quarter valued at approximately $1,127,000. Sigma Planning Corp increased its stake in Liquidia by 66.8% in the first quarter. Sigma Planning Corp now owns 51,255 shares of the company worth $368,000 after purchasing an additional 20,530 shares during the period. Qube Research & Technologies Ltd increased its stake in Liquidia by 368.7% in the 1st quarter. Qube Research & Technologies Ltd now owns 53,044 shares in the company worth $381,000 after purchasing an additional 41,727 shares during the period. Eversept Partners LP increased its stake in Liquidia by 55.8% in the 4th quarter. Eversept Partners LP now owns 1,447,898 shares of the company worth $7,051,000 after purchasing an additional 518,849 shares during the period. Finally, Sciencast Management LP acquired a new position in Liquidia in Q1 worth approximately $83,000. 35.79% of the shares are held by hedge funds and other institutional investors.

Liquidia shares down 16.1%

A d Legacy search

This little-known financial ‘hack’ could forever change the way Americans shop

The Financial Genius reveals how to buy anything you want – without paying as usual.

NASDAQ: LQDA traded down $0.93 during Thursday’s midday session, hitting $4.84. The company’s shares had a trading volume of 323,779 shares, compared to its average volume of 1,264,964. Liquidia has a 1-year low of $2.52 and a 1-year high of 8, $79. The stock has a fifty-day moving average of $5.43 and a 200-day moving average of $5.62. The company has a market capitalization of $311.51 million, a PE ratio of -5.93 and a beta of 0.34.

Liquidia (NASDAQ:LQDA – Get Rating) last released its quarterly earnings data on Thursday, August 11. The company reported ($0.15) earnings per share for the quarter, beating analyst consensus estimates of ($0.24) by $0.09. The company posted revenue of $3.92 million in the quarter, compared to $3.51 million expected by analysts. On average, analysts expect Liquidia to post -0.81 earnings per share for the current year.

Liquidia company profile

(Get a rating)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures and markets various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.

Recommended Stories

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Liquidia, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Liquidia wasn’t on the list.

Although Liquidia currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Comments are closed.